EcoDrugPlus

Neuropeptide Y Receptor Y2

Ensembl ID : ENSNGAG00000009340
Gene Symbol: NPY2R
3 Cross references
246 Possible Orthologues:

Neuropeptide Y Receptor Y4-2

Ensembl ID : ENSNGAG00000013978
Gene Symbol: NPY4R2
3 Cross references
116 Possible Orthologues:

Neuropeptide Y Receptor Y5

Ensembl ID : ENSNGAG00000022379
Gene Symbol: NPY5R
3 Cross references
135 Possible Orthologues:

Neurotensin Receptor 1

Ensembl ID : ENSNGAG00000021420
Gene Symbol: NTSR1
3 Cross references
211 Possible Orthologues:

Neurotrophic Receptor Tyrosine Kinase 1

Ensembl ID : ENSNGAG00000018474
Gene Symbol: NTRK1
3 Cross references
199 Possible Orthologues:

Neurotrophic Receptor Tyrosine Kinase 2

Ensembl ID : ENSNGAG00000018123
Gene Symbol: NTRK2
3 Cross references
286 Possible Orthologues:

Neurotrophic Receptor Tyrosine Kinase 3

Ensembl ID : ENSNGAG00000009651
Gene Symbol: NTRK3
3 Cross references
269 Possible Orthologues:

Neutrophil Elastase-Like

Ensembl ID : ENSNGAG00000001759
Gene Symbol: LOC103737354
3 Cross references
102 Possible Orthologues:

Nicastrin

Ensembl ID : ENSNGAG00000022047
Gene Symbol: NCSTN
3 Cross references
203 Possible Orthologues:

Nicotinamide Phosphoribosyltransferase

Ensembl ID : ENSNGAG00000003845
Gene Symbol: NAMPT
3 Cross references
235 Possible Orthologues:

Nischarin

Ensembl ID : ENSNGAG00000020164
Gene Symbol: NISCH
3 Cross references
209 Possible Orthologues:

Nitric Oxide Synthase 2

Ensembl ID : ENSNGAG00000014709
Gene Symbol: NOS2
3 Cross references
163 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).